Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Investigational New Drugs
Published in: Investigational New Drugs 4/2022

11-04-2022 | Sarcoma | Letters to the Editor

Synergistic activities of the histone deacetylase inhibitors with conventional cytotoxic chemotherapies in angiosarcomas

Authors: Yingjun Zhang, C. H. Wong, Herbert H. F. Loong

Published in: Investigational New Drugs | Issue 4/2022

Login to get access

Excerpt

To the Editor, …
Literature
1.
Wang L, de Oliveira RL, Huijberts S, Bosdriesz E, Pencheva N, Brunen D, Bosma A, Song J-Y, Zevenhoven J, Los-de Vries GT (2018) An acquired vulnerability of drug-resistant melanoma with therapeutic potential. Cell 173 (6):1413–1425. e1414
2.
Maiso P, Colado E, Ocio EM, Garayoa M, Martin J, Atadja P, Pandiella A, San-Miguel J (2009) The synergy of panobinostat plus doxorubicin in acute myeloid leukemia suggests a role for HDAC inhibitors in the control of DNA repair. Leukemia 23(12):2265–2274CrossRef
3.
Catalano MG, Poli R, Pugliese M, Fortunati N, Boccuzzi G (2007) Valproic acid enhances tubulin acetylation and apoptotic activity of paclitaxel on anaplastic thyroid cancer cell lines. Endocr Relat Cancer 14(3):839–845CrossRef
Metadata
Title
Synergistic activities of the histone deacetylase inhibitors with conventional cytotoxic chemotherapies in angiosarcomas
Authors
Yingjun Zhang
C. H. Wong
Herbert H. F. Loong
Publication date
11-04-2022
Publisher
Springer US
Published in
Investigational New Drugs / Issue 4/2022
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-022-01239-1

Other articles of this Issue 4/2022

Investigational New Drugs 4/2022 Go to the issue

PHASE I STUDIES

Eftozanermin alfa (ABBV-621) monotherapy in patients with previously treated solid tumors: findings of a phase 1, first-in-human study

PRECLINICAL STUDIES

NSC305787, a pharmacological ezrin inhibitor, exhibits antineoplastic activity in pancreatic cancer cells

Short Report

Practical consideration for successful sequential tumor biopsies in first-in-human trials

PHASE I STUDIES

A phase 1 safety and bioimaging trial of antibody DS-8895a against EphA2 in patients with advanced or metastatic EphA2 positive cancers

PHASE II STUDIES

Lenvatinib combined with nivolumab in advanced hepatocellular carcinoma-real-world experience

Letters to the Editor

A lung adenocarcinoma patient harboring MET c. 3028 + 2 T >A variant sensitive to crizotinib treatment
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits